Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)GlobeNewsWire • 12/04/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGNPRNewsWire • 10/18/25
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGNBusiness Wire • 10/01/25
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 10/01/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGNGlobeNewsWire • 09/24/25
Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?Zacks Investment Research • 08/28/25
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should KnowZacks Investment Research • 08/12/25
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 07/29/25
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025GlobeNewsWire • 07/22/25
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/21/25